Trials / Completed
CompletedNCT00243347
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
An Exploratory, Open-Lael Study to Assess the Effects of AZD2171 on Tumors and Biomarkers in Patients With Previously Untreated or Recurrent Non-small Cell Lung Cancer (NSCLC) or Patients With Metastatic or Recurrent Head and Neck Cancer (HNC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2171 | oral tablet |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2008-05-01
- Completion
- 2009-07-01
- First posted
- 2005-10-24
- Last updated
- 2013-10-17
- Results posted
- 2013-10-17
Locations
2 sites across 2 countries: United States, Spain
Source: ClinicalTrials.gov record NCT00243347. Inclusion in this directory is not an endorsement.